Spotlight on Endocrinology & Diabetes

Credits: 0.25 CME
Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Unmet Eye Care Needs in Diabetes Mellitus
Carl D. Regillo, MD, FACS
Medical Education Resources (MER)

Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Unmet Eye Care Needs in Diabetes Mellitus

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 15, 2020
Expires: May 15, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™ and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Growing incidence of diabetes
  • Diabetic retinopathy—a leading cause of blindness
  • Lack of awareness of eye disease risk among patients with diabetes
  • Dilated eye exam recommendations and frequency
  • Management and follow-up obstacles

Faculty

Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Carl D. Regillo, MD, FACS, has disclosed grant research funded by Allergan, Genentech, Novartis, Regeneron, Kodiak, Chengdu Kanghong, Opthea, Adverum, RegenxBio, and Graybug. Additionally, he has received consulting fees from Allergan, Genentech, Novartis, Chendu Kanghong, Kodiak, Adverum, and Graybug. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 15, 2020
Expires: May 15, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™ and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Growing incidence of diabetes
  • Diabetic retinopathy—a leading cause of blindness
  • Lack of awareness of eye disease risk among patients with diabetes
  • Dilated eye exam recommendations and frequency
  • Management and follow-up obstacles

Faculty

Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Carl D. Regillo, MD, FACS, has disclosed grant research funded by Allergan, Genentech, Novartis, Regeneron, Kodiak, Chengdu Kanghong, Opthea, Adverum, RegenxBio, and Graybug. Additionally, he has received consulting fees from Allergan, Genentech, Novartis, Chendu Kanghong, Kodiak, Adverum, and Graybug. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

Endocrinology & Diabetes Presentations

0.25 CME
Medical Education Resources (MER)
Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Unmet Eye Care Needs in Diabetes Mellitus

Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Unmet Eye Care Needs in Diabetes Mellitus

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 15, 2020
Expires: May 15, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™ and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Growing incidence of diabetes
  • Diabetic retinopathy—a leading cause of blindness
  • Lack of awareness of eye disease risk among patients with diabetes
  • Dilated eye exam recommendations and frequency
  • Management and follow-up obstacles

Faculty

Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Carl D. Regillo, MD, FACS, has disclosed grant research funded by Allergan, Genentech, Novartis, Regeneron, Kodiak, Chengdu Kanghong, Opthea, Adverum, RegenxBio, and Graybug. Additionally, he has received consulting fees from Allergan, Genentech, Novartis, Chendu Kanghong, Kodiak, Adverum, and Graybug. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 15, 2020
Expires: May 15, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™ and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Growing incidence of diabetes
  • Diabetic retinopathy—a leading cause of blindness
  • Lack of awareness of eye disease risk among patients with diabetes
  • Dilated eye exam recommendations and frequency
  • Management and follow-up obstacles

Faculty

Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Carl D. Regillo, MD, FACS, has disclosed grant research funded by Allergan, Genentech, Novartis, Regeneron, Kodiak, Chengdu Kanghong, Opthea, Adverum, RegenxBio, and Graybug. Additionally, he has received consulting fees from Allergan, Genentech, Novartis, Chendu Kanghong, Kodiak, Adverum, and Graybug. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

0.50 CME
Integrity Continuing Education, Inc.
Enhancing the Patient-Provider Connection: Practical Strategies for Improving Outcomes in Obesity Management

Enhancing the Patient-Provider Connection: Practical Strategies for Improving Outcomes in Obesity Management

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credits
Released: June 6, 2019
Expires: June 6, 2020
30 minutes to complete

Provided By

Target Audience

This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Analyze regional and ethnic disparities in obesity
  • Address patients with obesity with sensitivity and a greater understanding of this disorder’s causes, challenges, and treatments
  • Apply current practice guidelines to optimize screening, diagnosis, and treatment
  • Implement proven communication strategies, such as The 5 A’s of Obesity Counseling, to effectively engage patients in weight loss discussion
  • Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss

Activity Description

The U.S. Preventative Services Task Force and the American Academy of Pediatrics recommend that physicians screen patients for obesity and practice counseling interventions to achieve modest (4%-8%) weight loss. Despite this, physicians frequently do not document obesity, counsel, or initiate therapy for weight loss. Medically-managed weight loss may provide the safest and most effective means to initial weight loss and weight loss maintenance over time. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of health professionals. This program will improve family physicians’ skills and confidence in weight loss counseling and treatment while also discussing geographic, ethnic, and racial disparities.

Statement of Educational Need

In this CME activity, you will view video clips of unhelpful and helpful clinicians and expert faculty commentary to learn how to effectively and appropriately screen, diagnose, and treat patients with obesity.

Faculty

Deborah Bade Horn, DO, MPH
Deborah Bade Horn, DO, MPH
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Deborah Bade Horn, DO, MPH
Consulting Fees: Bausch Health/Valeant Pharmaceuticals International; Novo Nordisk, Inc.
Speakers’ Bureau: Novo Nordisk, Inc.
Contracted Research: Novo Nordisk, Inc.

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 6, 2019 through June 6, 2020 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk Inc. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Novo Nordisk Inc.

Activity Details

Free CME
0.50 AMA PRA Category 1 Credits
Released: June 6, 2019
Expires: June 6, 2020
30 minutes to complete

Provided By

Target Audience

This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Analyze regional and ethnic disparities in obesity
  • Address patients with obesity with sensitivity and a greater understanding of this disorder’s causes, challenges, and treatments
  • Apply current practice guidelines to optimize screening, diagnosis, and treatment
  • Implement proven communication strategies, such as The 5 A’s of Obesity Counseling, to effectively engage patients in weight loss discussion
  • Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss

Activity Description

The U.S. Preventative Services Task Force and the American Academy of Pediatrics recommend that physicians screen patients for obesity and practice counseling interventions to achieve modest (4%-8%) weight loss. Despite this, physicians frequently do not document obesity, counsel, or initiate therapy for weight loss. Medically-managed weight loss may provide the safest and most effective means to initial weight loss and weight loss maintenance over time. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of health professionals. This program will improve family physicians’ skills and confidence in weight loss counseling and treatment while also discussing geographic, ethnic, and racial disparities.

Statement of Educational Need

In this CME activity, you will view video clips of unhelpful and helpful clinicians and expert faculty commentary to learn how to effectively and appropriately screen, diagnose, and treat patients with obesity.

Faculty

Deborah Bade Horn, DO, MPH
Deborah Bade Horn, DO, MPH
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Deborah Bade Horn, DO, MPH
Consulting Fees: Bausch Health/Valeant Pharmaceuticals International; Novo Nordisk, Inc.
Speakers’ Bureau: Novo Nordisk, Inc.
Contracted Research: Novo Nordisk, Inc.

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 6, 2019 through June 6, 2020 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk Inc. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Novo Nordisk Inc.